Beijing Tong Ren Tang Chinese Medicine (3613) Renews PRC Distribution Framework Agreement with Annual Caps Set

Bulletin Express

Jan 20

Beijing Tong Ren Tang Chinese Medicine Company Limited (3613) entered into a renewed PRC distribution framework agreement with China Beijing Tong Ren Tang Group Co., Ltd. (Tong Ren Tang Holdings). Subject to Independent Shareholders’ approval at an extraordinary general meeting on 11 February 2026, the new term runs from 1 January 2026 to 31 December 2028. Under the arrangement, Tong Ren Tang Group, as a non-exclusive distributor, may purchase Chinese Medicine Products and Owned Products from the group for distribution in the PRC or for production use.

The proposed annual transaction caps under the renewed agreement are set at HK$230 million, HK$320 million, and HK$440 million for 2026, 2027, and 2028, respectively. Prices for products will be determined with reference to prevailing market rates or on a cost-plus basis for Owned Products, ensuring that the terms to Tong Ren Tang Group are no more favorable than those offered to independent third parties. The board of directors indicates that entering into this arrangement continues to align with business development interests, given Tong Ren Tang Group’s distribution network in the PRC.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1180203822"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1180203822\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1180203822?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-20 17:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180203822","market":"hk","top_or_hot":-1,"title":"Beijing Tong Ren Tang Chinese Medicine (3613) Renews PRC Distribution Framework Agreement with Annual Caps Set","media":"Bulletin Express","content":"<p>Beijing Tong Ren Tang Chinese Medicine Company Limited (3613) entered into a renewed PRC distribution framework agreement with China Beijing Tong Ren Tang Group Co., Ltd. (Tong Ren Tang Holdings). Subject to Independent Shareholders’ approval at an extraordinary general meeting on 11 February 2026, the new term runs from 1 January 2026 to 31 December 2028. Under the arrangement, Tong Ren Tang Group, as a non-exclusive distributor, may purchase Chinese Medicine Products and Owned Products from the group for distribution in the PRC or for production use.</p>\n<p>The proposed annual transaction caps under the renewed agreement are set at HK$230 million, HK$320 million, and HK$440 million for 2026, 2027, and 2028, respectively. Prices for products will be determined with reference to prevailing market rates or on a cost-plus basis for Owned Products, ensuring that the terms to Tong Ren Tang Group are no more favorable than those offered to independent third parties. The board of directors indicates that entering into this arrangement continues to align with business development interests, given Tong Ren Tang Group’s distribution network in the PRC.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Tong Ren Tang Chinese Medicine (3613) Renews PRC Distribution Framework Agreement with Annual Caps Set</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Tong Ren Tang Chinese Medicine (3613) Renews PRC Distribution Framework Agreement with Annual Caps Set\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-01-20 17:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Tong Ren Tang Chinese Medicine Company Limited (3613) entered into a renewed PRC distribution framework agreement with China Beijing Tong Ren Tang Group Co., Ltd. (Tong Ren Tang Holdings). Subject to Independent Shareholders’ approval at an extraordinary general meeting on 11 February 2026, the new term runs from 1 January 2026 to 31 December 2028. Under the arrangement, Tong Ren Tang Group, as a non-exclusive distributor, may purchase Chinese Medicine Products and Owned Products from the group for distribution in the PRC or for production use.</p>\n<p>The proposed annual transaction caps under the renewed agreement are set at HK$230 million, HK$320 million, and HK$440 million for 2026, 2027, and 2028, respectively. Prices for products will be determined with reference to prevailing market rates or on a cost-plus basis for Owned Products, ensuring that the terms to Tong Ren Tang Group are no more favorable than those offered to independent third parties. The board of directors indicates that entering into this arrangement continues to align with business development interests, given Tong Ren Tang Group’s distribution network in the PRC.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03613","symbol_name":"同仁堂国药","start_time":0,"source_url":"","article_id":"1180203822","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180203822","pubTimestamp":1768902215,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Beijing Tong Ren Tang Chinese Medicine Company Limited (3613) entered into a renewed PRC distribution framework agreement with China Beijing Tong Ren Tang Group Co., Ltd. (Tong Ren Tang Holdings)....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03613":"同仁堂国药"},"translate_title":"北京同仁堂中药(3613)重续中国分销框架协议并设定年度上限","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03613":1},"content_text":"Beijing Tong Ren Tang Chinese Medicine Company Limited (3613) entered into a renewed PRC distribution framework agreement with China Beijing Tong Ren Tang Group Co., Ltd. (Tong Ren Tang Holdings). Subject to Independent Shareholders’ approval at an extraordinary general meeting on 11 February 2026, the new term runs from 1 January 2026 to 31 December 2028. Under the arrangement, Tong Ren Tang Group, as a non-exclusive distributor, may purchase Chinese Medicine Products and Owned Products from the group for distribution in the PRC or for production use.\nThe proposed annual transaction caps under the renewed agreement are set at HK$230 million, HK$320 million, and HK$440 million for 2026, 2027, and 2028, respectively. Prices for products will be determined with reference to prevailing market rates or on a cost-plus basis for Owned Products, ensuring that the terms to Tong Ren Tang Group are no more favorable than those offered to independent third parties. The board of directors indicates that entering into this arrangement continues to align with business development interests, given Tong Ren Tang Group’s distribution network in the PRC.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}